Molecular Profile Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

Profile Name PDGFRA V561D PDGFRA D842V
Gene Variant Detail

PDGFRA D842V (gain of function)

PDGFRA V561D (gain of function)

Relevant Treatment Approaches


  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"


  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
PDGFRA V561D PDGFRA D842V gastrointestinal stromal tumor resistant Imatinib Case Reports/Case Series Actionable In a clinical study, PDGFRA D842V was identified as a secondary mutation in a patient with gastrointestinal stromal tumor harboring a primary PDGFRA V561D mutation, who developed resistance to Gleevec (imatinib mesylate) (PMID: 16954519). 16954519
PDGFRA V561D PDGFRA D842V Advanced Solid Tumor resistant Sunitinib Preclinical - Cell culture Actionable In a preclinical study, PDGFRA D842V conferred resistance to inhibition of PDGFRA phosphorylation by Sutent (sunitinib) in cells expressing PDGFRA V561D in culture (PMID: 18955458). 18955458
Clinical Trial Phase Therapies Title Recruitment Status